[1] Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O'Connor KC. B cells in the pathophysiology of myasthenia gravis[J]. Muscle Nerve, 2018, 57:172-184. [2] Liu Y, Liu R, Hao HJ, Zhao GP, Gao F. Detection and clinical significance of serum autoantibodies in patients with myasthenia gravis[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2016, 16:678-683.[刘云,刘冉,郝洪军,赵桂萍,高枫.重症肌无力患者血清学标志物检测及临床意义[J].中国现代神经疾病杂志, 2016, 16:678-683.] [3] Garraud O, Borhis G, Badr G, Degrelle S, Pozzetto B, Cognasse F, Richard Y. Revisiting the B-cell compartment in mouse and humans:more than one B-cell subset exists in the marginal zone and beyond[J]. BMC Immunol, 2012, 13:63. [4] Figgett WA, Vincent FB, Saulep-Easton D, Mackay F. Roles of ligands from the TNF superfamily in B cell development, function, and regulation[J]. Semin Immunol, 2014, 26:191-202. [5] Vale AM, Schroeder HW Jr. Clinical consequences of defects in B-cell development[J]. J Allergy Clin Immunol, 2010, 125:778-787. [6] Neuroimmunology Group, Neurology Branch, Chinese Medical Association; Neuroimmunology Branch, Chinese Society for Immunology. Guidelines for diagnosis and treatment of myasthenia gravis in China 2015[J]. Zhonghua Shen Jing Ke Za Zhi, 2015, 48:934-940.[中华医学会神经病学分会神经免疫学组,中国免疫学会神经免疫学分会.中国重症肌无力诊断和治疗指南2015[J].中华神经科杂志, 2015, 48:934-940.] [7] Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis:recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America[J]. Neurology, 2000, 55:16-23. [8] Muto K, Matsui N, Unai Y, Sakai W, Haji S, Udaka K, Miki H, Furukawa T, Abe M, Kaji R. Memory B cell resurgence requires repeated rituximab in myasthenia gravis[J]. Neuromuscul Disord, 2017, 27:918-922. [9] Han Y, Jin Y, Miao Y, Shi T, Lin X. Improved RANKL expression and osteoclastogenesis induction of CD27+CD38- memory B cells:a link between B cells and alveolar bone damage in periodontitis[J]. J Periodontal Res, 2019, 54:73-80. [10] Stathopoulos P, Kumar A, Nowak RJ, O'Connor KC. Autoantibody-producing plasma blasts after B cell depletion identified in muscle-specific kinase myasthenia gravis[J]. JCI Insight, 2017, 2:94263. [11] Suryani S, Tangye SG. Therapeutic implications of advances in our understanding of transitional B-cell development in humans[J]. Expert Rev Clin Immunol, 2010, 6:765-775. [12] Yilmaz V, Maillard S, Truffault F, Bolgert F, Behin A, Regnard JF, Berrih-Aknin S, Le Panse R. Regulatory B cells in myasthenia gravis are differentially affected by therapies[J]. Ann Clin Transl Neurol, 2018, 5:1408-1414. [13] Monteiro A, Cruto C, Rosado P, Rosado L, Fonseca AM, Paiva A. Interferon-beta treated-multiple sclerosis patients exhibit a decreased ratio between immature/transitional B cell subset and plasmablasts[J]. J Neuroimmunol, 2019, 326:49-54. [14] Stathopoulos P, Kumar A, Heiden JA, Pascual-Goñi E, Nowak RJ, O'Connor KC. Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis[J]. Ann NY Acad Sci, 2018, 1412:154-165. [15] Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, Galassi G. Factors affecting outcome in ocular myasthenia gravis[J]. Int J Neurosci, 2018, 128:15-24. [16] Sheng JR, Rezania K, Soliven B. Impaired regulatory B cells in myasthenia gravis[J]. J Neuroimmunol, 2016, 297:38-45. [17] Lu Y, Meng F, Yang Y, Li L, Wang D, Cui Y, Dong S, Wang W. Significance of B10 cell in patients with thymoma complicated with myasthenia gravis[J]. Oncotarget, 2017, 8:73774-73786. [18] Quan C, ZhangBao J, Lu J, Zhao C, Cai T, Wang B, Yu H, Qiao J, Lu C. The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy[J]. J Neuroimmunol, 2015, 282:45-53. [19] Gudbrandsdottir S, Brimnes M, Køllgaard T, Hasselbalch HC,Nielsen CH. Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia[J]. Eur J Haematol, 2018, 100:45-52. |